Drug Type Small molecule drug |
Synonyms (5α,6α)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (ester), 3,6-Diacetylmorphine, 7,8-Dihydro-4,5-alpha-epoxy-17-methylmorphinan-3,6-alpha-diol diacetate + [4] |
Target |
Action antagonists |
Mechanism Opioid receptors antagonists(Opioid receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (16 Feb 2022), |
Regulation- |
Molecular FormulaC21H24ClNO5 |
InChIKeyFZJYQGFGNHGSFX-PVQKIFDLSA-N |
CAS Registry1502-95-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Diamorphine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Opioid abuse | Canada | 16 Feb 2022 | |
Pain | - | - | - |
Phase 3 | 202 | ojfqzrqfcu(rjlpfgtfge): mean difference = -1.44 (90% CI, -3.22 to 0.27) View more | Positive | 01 May 2016 | |||
Injectable hydromorphone | |||||||
Not Applicable | 484 | moflzlbwck(abobupmzyz) = dhwmsajvle amkwmgntwx (gxskumhyzi, 39 - 124) View more | - | 01 Mar 2014 |